Karama Asleh

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 9

Top Topics

Metastatic Breast Cancer

Sentinel Lymph Node

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of experimental & clinical cancer research : CR

NPJ breast cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Karama Asleh, Gian Luca Negri, Sandra Elizabeth Spencer, Shane Colborne, Christopher S Hughes, Xiu Q Wang, Dongxia Gao, C Blake Gilks, Stephen K L Chia, Torsten O Nielsen, Gregg B Morin
Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes. Nature communications 13 (1) (2022)
Karama Asleh, Ana Lluch, Angela Goytain, Carlos Henrique Barrios, Xue Qi Wang, Laura Torrecillas, Dongxia Gao, Manuel Ruiz Borrego, Samuel C Y Leung, Jose Bines, Angel L Guerrero-Zotano, José Angel García-Saenz, Juan Miguel Cejalvo, Jesus Herranz, Roberto Torres, Juan R De la Haba-Rodríguez, Francisco Ayala, Henry L Gómez, Federico Rojo, Torsten O Nielsen, Miguel Martin
Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Karama Asleh, Nazia Riaz, Torsten O Nielsen
Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. Journal of experimental & clinical cancer research : CR 41 (1) (2022)
Elahe Shenasa, Elisabeth Specht Stovgaard, Maj-Britt Jensen, Karama Asleh, Nazia Riaz, Dongxia Gao, Samuel C Y Leung, Bent Ejlertsen, Anne-Vibeke Laenkholm, Torsten O Nielsen
Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical Trial. Cancers 14 (15) (2022)
Karama Asleh, Dongsheng Tu, Dongxia Gao, Vivien Bramwell, Mark N Levine, Kathleen I Pritchard, Lois E Shepherd, Torsten O Nielsen
Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (23) (2021)
Karama Asleh, Nazia Riaz, Angela S Cheng, Dongxia Gao, Samuel C Y Leung, Meenakshi Anurag, Torsten O Nielsen
Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. NPJ breast cancer 7 (1) (2021)
Karama Asleh, Heather Ann Brauer, Amy Sullivan, Susanna Lauttia, Henrik Lindman, Torsten O Nielsen, Heikki Joensuu, E Aubrey Thompson, Saranya Chumsri
Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (11) (2020)
Karama Asleh, Stina Lyck Carstensen, Charlotte L Tykjaer Jørgensen, Samantha Burugu, Dongxia Gao, Jennifer R Won, Maj-Britt Jensen, Eva Balslev, Anne-Vibeke Laenkholm, Dorte L Nielsen, Bent Ejlertsen, Torsten O Nielsen
Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial. International journal of cancer 144 (10) (2018)
Karama Asleh, Jennifer R Won, Dongxia Gao, K David Voduc, Torsten O Nielsen
Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up. Breast cancer research and treatment 168 (1) (2017)